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Abstract
Background Surgicalsiteinfection(SSI)isacommontype
of healthcare-associated infection in gastrointestinal (GI)
surgical procedures, which often has major consequences
for patient recovery and increased healthcare costs due to
prolonged hospital stay. This article provides an overview
of the efﬁcacy and safety of prophylactic application of
resorbable gentamicin-containing collagen implants (GCI)
in the prevention of SSI following high-risk GI surgical
procedures.
Method Nine publications were identiﬁed using the
PubMed online database and search terms ‘gentamicin
collagen implant’ plus ‘surgical site infection’, ‘wound
infection’ and ‘gastrointestinal surgery’.
Results Data from 483 patients treated prophylactically
have demonstrated that GCI can reduce the wound infec-
tion rate in high-risk GI surgical procedures and improve
wound healing after pilonidal sinus excision. In a study of
221 patients who underwent colorectal surgery, the wound
infection rate was reduced to 5.6% in the GCI group
compared to 18.4% in the control group (P\0.01). GCI
also positively inﬂuences the post-operative course for
patients undergoing particularly risky procedures e.g.
abdominoperineal resection (APR) combined with neo-
adjuvant radiotherapy. In one such patient series, GCI
reduced the wound infection rate by over 70% and the
length of hospital stay by 40%. Few side effects of GCI
were noted in the 9 clinical studies.
Conclusions This review demonstrates that GCI can have
a positive effect on wound infection rates in high-risk GI
surgery and can also improve wound healing after pilonidal
sinus excision.
Keywords Collagen  Collagen implant  Gentamicin 
Rectal surgery  Surgical site infection  Wound infection
Introduction
Surgical site infection (SSI) is a common type of health-
care-associated infection, which often has major conse-
quences for patient recovery and increased healthcare costs
due to prolonged hospital stay.
The risk of a patient developing an SSI is related to
comorbidities, type of procedure and other factors such as
length of surgery and use of prosthetic implants [1–3]. Data
from national and regional surveys and single studies have
highlighted high SSI rates in gastrointestinal (GI) surgical
procedures (e.g. elective colorectal resection) [4–6]. Some
of the higher rates of SSI in GI surgery are associated with
newer techniques aimed at improving local control and
resectability of the tumour, e.g. pre-operative radiotherapy
followed by abdominoperineal resection (APR) [7, 8].
Therefore, there is a need for better prevention of SSIs
following GI surgery in order to improve patient morbidity
and decrease healthcare costs.
The mainstay of SSI prevention in addition to strict
aseptic surgical technique is the use of antibiotic prophyl-
axis administered systemically both pre- and post-
operatively.
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systematic review showed consistently that the wound
infection rate was much lower in the antibiotic groups than
that in the control groups (13% versus 40%; OR 4.08, 95%
CI (c.i) 2.33–7.13) [9]. However, following GI surgery
there is a tendency to administer systemic antibiotics for
longer time periods, despite the fact that this may not
necessarily lower the risk of SSI and this may in turn lead
to a greater risk of antibiotic resistance [9–12].
The emergence of technologies such as resorbable gen-
tamicin-containing collagen implants (GCI), which deliver
high local concentrations of gentamicin with correspond-
ingly low serum levels offer a means of reducing SSI rates
following GI surgery, lowering the risk of antibiotic resis-
tance by reducing the need for long-term administration of
systemic antibiotics, avoiding toxicity associated with sys-
temic antibiotics, and avoiding the need for reoperation as
the implant is fully resorbable. The use of collagen as a
carrier also has positive effects on wound healing.
GCI seems to limit the risk of SSI in several ways.
Collagen causes faster coagulation to stop bleeding [13]
and reduces the risk of seroma and haematoma formation
that can in turn accelerate bacterial proliferation [14, 15].
The breakdown of the GCI by macrophage collagenases
increases the number of collagen ﬁbres released, which
attracts ﬁbroblasts and stimulates the ﬁbroblasts to prolif-
erate and lay down new collagen in the healing process [13].
Immune responses against collagen implants are
uncommon [13, 16, 17], whereas collagen implants act as
effective drug carriers [18, 19]. Drugs are released from the
collagen matrix by a combination of diffusion and natural
enzymatic breakdown of the collagen matrix providing
rapid (diffusion) and prolonged (breakdown of the matrix)
drug release [19].
The antimicrobial proﬁle of gentamicin seems to be
appropriate for use with GCI. Gentamicin allows sterili-
sation of the implants by gamma rays and does not seem to
affect the collagen clotting features, as discussed above
[16, 20]. The local use of gentamicin delivers a bactericidal
concentration that is much higher than that allowed by
systemic injection, so antibiotic blood concentrations
remain low and reduce the chance of adverse effects (e.g.
nephrotoxicity), while the local drug concentrations are
kept high for at least 48 h [21, 22]. In this way, resistance
to antibiotics caused by low drug dosage is avoided [23],
and gentamicin behaves like a broad spectrum antibiotic
[21, 23].
A number of resorbable GCI are available worldwide.
The objective of this article is to review all published
clinical data regarding prophylactic application of resorb-
able GCI following GI surgery in order to provide an
overview of the efﬁcacy and safety of GCI for speciﬁc
indications with particular focus on high-risk procedures.
Method
The candidate publications were identiﬁed using the
National Library of Medicine’s PubMed online search
utility and the search term ‘gentamicin collagen implant’
plus ‘surgical site infection’, ‘wound infection’ and ‘gas-
trointestinal surgery’. This search identiﬁed 28 potential
publications. Nine publications focusing speciﬁcally on GI
surgery and related areas (e.g. pilonidal sinus resection)
were selected. These studies concerned the use of two GCI
i.e. Collatamp
 (EUSA Pharma [Europe], Oxford, United
Kingdom) and Septocoll
 (Biomet Deutschland GmbH,
Berlin, Germany). Collatamp contains 2 mg/cm
2 gentami-
cin sulphate. The collagen in Collatamp, present at 2.8 mg/
cm
2, is type I collagen from a renatured bovine or equine
source. Septocoll contains gentamicin sulphate (70 mg
gentamicin from 116 mg gentamicin sulphate base in a
10 cm 9 8 cm implant) and gentamicin crobefate (70 mg
gentamicin from 350 mg gentamicin crobefate in a
10 cm 9 8 cm implant). Septocoll contains type I collagen
from a renatured equine source.
The outcome measures of primary interest were SSI rate
(superﬁcial and deep), primary and secondary healing rate
together with post-operative and surgical complication rate.
Other outcome measures include time to complete wound
healing; operating time; length of hospital stay; tumour
recurrence (local and distant); survival time; pain score;
analgesic use and cost. The level of evidence for each study
was graded according to the criteria developed by Carru-
thers et al. [24] (see Table 1).
Clinical experience
To date, there have been 9 clinical studies which have
focused on the local application of GCI in the prophylaxis
of SSI following gastrointestinal surgery (Table 2). Six
studies were of what would be considered procedures at
high-risk of SSI and three of procedures at medium-risk.
Eight of the studies were of randomised, controlled design,
and one included a consecutive patient series with con-
temporaneous controls. Seven of the studies were graded as
level 1 (see Table 2). Taken together these studies repre-
sent experience with 483 patients treated prophylactically
with GCI (n = 383 with Collatamp and n = 100 with
Septocoll) following GI surgery.
Rectal surgery
There is a growing body of data to support the use of GCI
following high-risk GI surgical procedures to reduce
wound infection rates, wound healing time and length of
hospital stay. Three randomised trials have assessed the
effect of GCI in rectal tumour resection. Rutten and
302 Tech Coloproctol (2010) 14:301–310
123colleagues undertook a randomised study in which 221
patients undergoing a range of colorectal surgical proce-
dures were randomised to the application of GCI plus
systemic antibiotics (Group I) or systemic antibiotics alone
(Group II) (Table 2)[ 25]. There was a signiﬁcantly lower
rate of post-operative wound infection in Group I
(P\0.01). The difference between the 2 groups was
maintained even when patients with multiple complications
were excluded (P\0.05). The patients in Group I also had
a signiﬁcantly shorter hospital stay when compared to
those in Group II (P = 0.015). However, after exclusion of
the patients with complications unrelated to wound infec-
tion, the difference between the two groups diminished,
with the median stay in Group I being one day shorter than
Group II (13 vs. 14 days, respectively).
A second randomised, single centre study, in a similar
group of patients (n = 229) treated with application of GCI
plus systemic antibiotics (Group I), or systemic antibiotics
alone (Group II) [26] (Table 2), reported a signiﬁcantly
lower post-operative complication rate (including wound
infection) at 30 days in Group I (P = 0.0441). Sub-group
analysis also revealed that this difference was maintained in
patients at even higher risk of post-operative complications
i.e. in those whose surgery exceeded 3 h (P = 0.0314) and
those who experienced intraoperative bowel perforation
(P = 0.01). The patients in Group I also had signiﬁcantly
lower rates of cancer recurrence (local or metastasic)
(P = 0.03) and increased overall and disease-free survival
(at 3 years). However, the reasons for this are unclear, and
further studies are required to conﬁrm these results and
clarify the mechanisms involved.
A third randomised, single blind, multicentre study by
Gru ¨ssner and colleagues focused speciﬁcally on 97 patients
undergoing abdominoperineal resection (APR) of the
anorectum, which is associated with a particularly high risk
of infection and other post-operative complications as
already discussed [27]. Patients were randomised to treat-
ment with application of GCI; systemic antibiotics plus
sacral drainage (Group I) or systemic antibiotics plus sacral
drainage (Group II). The patients in Group I had a signif-
icantly lower rate of perineal wound infections (P\0.05)
and secondary complications with infection (P\0.05)
compared to those in Group II. In addition, patients in
Group I had a much greater reduction in the number of
pathogens in the post-operatively obtained wound secretion
samples compared to Group II (P = 0.013).
In a recent publication, we studied for the ﬁrst time the
effect of GCI in patients undergoing APR following short-
term, neoadjuvant radiotherapy. This study consisted of a
consecutive series of 40 subjects. All patients received
pre-operative radiation (5 Gy daily for 5 days) followed by
a typical APR using the total mesorectal excision tech-
nique. Patients were then treated with application of GCI,
systemic antibiotics plus sacral drainage (Group I) or sys-
temic antibiotics plus sacral drainage (Group II) [28]
(Table 2). This study demonstrated signiﬁcantly lower
rates of wound infection (P = 0.05) and signiﬁcantly
higher rates of primary wound healing (P\0.01) in Group
I. The patients in Group I also had signiﬁcantly shorter
mean hospital stays compared to those in Group II
(P = 0.04).
Abdominal surgery
Two randomised studies have assessed the effect of the
prophylactic application of GCI in various types of
abdominal surgery. Gomez and colleagues randomised 73
patients to the application of GCI plus systemic antibiotics
(Group I) and primary wound closure or systemic anti-
biotics and an open wound technique for the prophylaxis of
infection in abdominal wounds that were ‘dirty’(e.g. due to
colon perforation) (Group II) [29] (Table 2). Patients in
Group I had a statistically signiﬁcant lower wound infec-
tion rate (P\0.001). The difference between the two
groups showed that the application of GCI made prophy-
laxis four times more effective. Similarly, good results
were also evident in Group I for time to wound healing; in
Group I, patients took an average of 10.31 days to heal
compared to 15.20 days in Group II (P\0.001). Given the
lower rate of wound infection and the quicker time to
healing, patients in Group I spent an average of 1.55 days
less in hospital compared to those in Group II.
A second, randomised study focused speciﬁcally on the
effect of GCI on the incidence of wound infection
Table 1 Levels of evidence for rating studies [25]
Level Deﬁnition of evidence
1 Randomised, controlled trial (RCT) that demonstrated a
statistically signiﬁcant difference in at least one important
outcome
OR
If the difference is not statistically signiﬁcant, an RCT of
adequate sample size to exclude a 25% difference in relative
risk with 80% power, given the observed results
2 RCT that does not meet level 1 criteria
3 Non-randomized trial with contemporaneous controls selected
by some systematic method (i.e. not selected by perceived
suitability for one of the treatment options for individual
patients)
OR
Subgroup analysis of a randomised trial
4 Before-after study or case series (of C10 patients) with
historical controls or controls drawn from other studies
5 Case series (of C10 patients) without controls
6 Case reports (of\10 patients)
Tech Coloproctol (2010) 14:301–310 303
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123following loop-ileostomy closure [30] (Table 2). Eighty
patients were randomised to the application of GCI or
identical collagen implants without gentamicin. There was
no statistical difference in the rate of wound infections or
surgical complications between the two groups. The
infection rate in both groups was much lower than previ-
ously reported with this type of procedure [31–33].
Pilonidal sinus excision
Three randomised studies have assessed the effectiveness
of GCI in patients undergoing pilonidal sinus excision with
primary wound closure [34–36]. Vogel and colleagues
randomised 80 patients to the application of GCI with
primary wound closure (Group I) or primary closure alone
(Group II) [34]. The wound in both groups was closed with
1–2 layers of subcutaneous sutures (carefully avoiding any
cavity formation) plus skin sutures. The primary healing
rate was signiﬁcantly higher in Group I with over twice the
number of patients with wounds that healed post-opera-
tively compared to Group II (P\0.001). The patients in
Group I also had a signiﬁcantly lower secondary healing
rate overall (P\0.001). With this procedure, less than
10% of the patients had post-operative abscess formation in
Group I, in contrast with over half of the patients in Group
II (P\0.001). At 1-year follow-up, no recurrence had
occurred in either group.
The second randomised study of pilonidal sinus excision
randomised 103 patients to GCI plus primary closure
(Group I) or open treatment (Group II), in order to compare
surgical techniques for this indication [35]. In Group I, 14
(27%) patients failed to achieve primary healing. Five of
these required conversion to open treatment and 9 experi-
enced spontaneous wound dehiscence. Thus overall 37
(73%) patients experienced primary healing at 2 weeks.
Wound breakdown was caused either by seroma formation
or spontaneous dehiscence; however, complete healing of
the failures by secondary intention occurred in almost all
patients at 6 and 26 weeks.
Despite a failure rate of 27%, the median time to com-
plete wound healing was signiﬁcantly shorter in Group I.
Patients in Group II took almost four times as long to heal
compared to patients in Group I (P = 0.0001). Despite the
longer healing time in Group II, there was no signiﬁcant
difference between the two groups in mean length of
hospital stay. One recurrent pilonidal sinus was seen in
Group I and none in Group II in the 26-week follow-up
period.
The third study of this indication for GCI use random-
ised 60 patients to GCI plus primary closure (Group I) or
open treatment (Group II) and followed patients to assess
recurrence rates at 5 years [36]. The excision with primary
sutures utilised in Group I took a signiﬁcantly longer time
(mean: 23 min) than the open method used in Group II
(mean: 14 min) (P\0.0001).
Signiﬁcantly more wounds in Group I had healed
completely compared to Group II at 4 weeks (P\0.001).
Furthermore, the wounds in Group I healed in a signiﬁ-
cantly shorter time compared to those in Group II
(P\0.001). There was no difference seen between the two
groups in length of hospital stay.
The closed wounds in Group I required fewer dressings
(mean 2) when compared to open wounds in Group II
(mean 25) (P\0.001). The patients in Group I also
experienced signiﬁcantly less pain on post-operative days
2, 4 and 7 (as reﬂected by their linear analogue pain scores)
compared to the patients in Group II (P\0.02). This
resulted in less oral analgesic use in Group I. However, the
difference between the two groups did not reach statistical
signiﬁcance at any time point.
Despite the lack of difference seen in length of hospital
stay between the two groups, the overall cost per patient
(calculated as hospital stay, cost of materials e.g. dressings
and district nursing costs) was signiﬁcantly lower for
patients in Group I (mean of £149) compared to those in
the open Group II (mean of £660) (P\0.001). Recurrence
rates were similar at 5-year follow-up.
Discussion
SSI is a common but potentially avoidable complication
following GI surgery [37]. SSIs have signiﬁcant impact on
patient morbidity, mortality, QOL and resource utilisation
and therefore, there is a need for more effective prevention
in high-risk patients and procedures. There is a lack of
evidence that prolonged prophylactic antibiotics reduce
SSI rates and this approach may lead to antibiotic resis-
tance. However, as early as 1997, Rutten and colleagues
demonstrated the efﬁcacy of locally applied gentamicin
(with systemic antibiotics) in lowering the risk of antibiotic
resistance.
This review has demonstrated that GCI can reduce the
wound infection rate in high-risk GI surgery and improve
wound healing after pilonidal sinus excision. GCI can also
positively inﬂuence the post-operative course of patients
undergoing particularly risky procedures e.g. APR com-
bined with neoadjuvant radiotherapy. De Bruin and col-
leagues demonstrated that GCI reduced the wound
infection rate by over 70% and the length of hospital stay
by 40% in a series of patients who underwent pre-operative
radiotherapy followed by APR [28].
Of the nine studies reviewed, one did not show any sig-
niﬁcant beneﬁt of local application of GCI compared to
systemicantibioticsalone.Haaseetal.showednoadditional
beneﬁt of GCI following loop-ileostomy closure. However,
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123the study did have an extremely low SSI rate in the control
group (10%) in contrast to that found in the literature (up to
41%ofpatients)[32–34,38,39].Thelackofeffectseenwith
GCI may therefore be related to the use of a collagen-only
implant in the ‘control’ group which, as discussed before,
may not be a true ‘control’ as collagen on its own has also
been shown to positively impact wound healing.
Few adverse side effects were reported in these studies
[26–31, 35, 36]. However, in our experience, the dissolution
of the GCI may result in an increase in wound secretion but
this does not seem to have further consequences for wound
healing.Gentamicinisanaminoglycosideantibioticthathas
the potential to induce severe nephrotoxicity and acute renal
failure when used at high concentrations [40]. However,
systemic concentrations of gentamicin with implantation of
1–5 GCI remain well below the established toxicity
thresholds of 10–12 lg/ml for peak values and eventually
fallbelow2 lg/mlby24 h[22].InamulticentretrialofGCI
in sternal wound infections, no difference in post-operative
renal function was noted [41]. The effects of GCI in patients
with chronic renal failure are still unknown and caution is
warranted [42].
This review on the efﬁcacy of GCI has brought up
several topics which warrant further investigation. Bin-
nebo ¨sel and colleagues have discovered that intra-abdom-
inal applied gentamicin can enhance the healing of
anastomosis and increase the collagen type I/type III in a
rat model [43]. This may have positive implications for
patients undergoing pilonidal sinus excision as the same
group showed a decrease of extracellular matrix (ECM)
and collagen in patients who with delayed wound healing
[44]. Junge et al. also demonstrated that the quality of
collagen formation was signiﬁcantly increased when gen-
tamicin was used to supplement a polyvinylidenﬂouride
mesh material used in order to improve scar quality and
mesh integration in hernia repair [45, 46]. Although this
and other data suggest a positive effect of local gentamicin
on collagen content and metabolism, there is conﬂicting
data regarding this subject. Vaneerdeweg et al. studied the
inﬂuence of GCI on the healing of colonic anastomoses in a
rat model of peritonitis [47]. The rats where divided into
four groups: control; collagen implant, intravenous (IV)
gentamicin and GCI. No signiﬁcant difference in bursting
pressure was seen between the control, IV gentamicin and
GCI groups. Almost all rats in the collagen group had
anastomotic leakage, suggesting that collagen alone may
be a focus for infection and anastomotic breakdown. The
Vaneerdeweg data conﬂicts with that of Haase et al. who
demonstrated that collagen had a beneﬁcial effect in their
‘collagen alone’ group compared to the wound infection
rate in the literature following loop-ileostomy closure.
Therefore, further work is required to elicit the mechanism
involved and the implications for GCI use.
Additional study is also required to evaluate the health
economic beneﬁt of GCI. The clinical data reviewed here
has demonstrated a positive effect on the length of hospital
stay with GCI after rectal tumour resection. In our recently
published study, the difference in the length of hospital
stay between the two groups was 10 days and this may
indicate a potentially large saving in hospital costs per
patient treated prophylactically with GCI following APR.
In addition, overall costs were shown to be signiﬁcantly
reduced with GCI following pilonidal sinus excision in a
small series of patients.
Utilising data from Rutten et al., and length of stay
information from a UK-based survey on the adverse effects
of SSI [48] the cost-beneﬁt of GCI can be estimated. Based
on 100 patients undergoing bowel surgery, the total cost
saving due to reduction in length of hospital stay with GCI
would be approximately £16,000. However, there has been
no study to date which has utilised health economic end-
points in order to prospectively analyse the potential direct
and indirect costs savings with GCI in high-risk GI surgical
procedures.
Conclusions
Prophylactic use of gentamicin-containing collagen im-
plants seems to be safe and simple to use, but does it work?
ThisreviewdemonstratesthatGCIcanhaveapositiveeffect
onwoundinfectionratesinhigh-riskGIsurgeryandcanalso
improve wound healing after pilonidal sinus excision.
No serious side effects were noted in this review sug-
gesting the prophylactic use of GCI in GI surgery is safe.
Due to the different patient populations, types of study and
inclusion/exclusion criteria, a meta-analysis would be chal-
lenging to perform. Therefore, randomised trials with well-
described patient categories, end points and follow-up could
help to conﬁrm the positive effect of GCI on wound healing,
and at the same time evaluate their health economic beneﬁt
and investigate their potential effect on collagen metabolism.
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